EN DE
Watch Fermentalg SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Fermentalg SA (ALGAE) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Fermentalg SA stock €0.35, price €0.39, that is 9.7% below the price, quality 41 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR

FS Fermentalg SA logo Thin data Nov 10, 2026

Fermentalg SA

ALGAE · PA
Expensive, weak quality

Our calculation puts a fair price 10% below what the stock costs today.

Low debt
Quality 41/100
Expensive Growth (revenue 5y +43.4 %/yr in EUR)
Mixed vs. peers (4/10)
Fair value €0.3522 · Overvalued
Loss-making · -70.6% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Fermentalg SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.42 €0.2300 Fair Value €0.3522 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range €0.2300 – €3.42 · fair‑value band €0.2642 – €0.4403 · the €0.3900 price screens above the €0.3522 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Fermentalg in your weekly email

Every Wednesday you see whether Fermentalg is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Fermentalg SA provides biosolutions based on aquatic micro-organisms in Europe, North America, Asia, and internationally.

Show moreShow less

It offers DHA ORIGINS, a plant-based DHA oil; KALVEA PLUS, a nutritious algal protein concentrate dedicated to aquafeed applications; Everzure, an extract of natural acid stable blue color; BLUE ORIGINS AOX, an antioxidant and anti-inflammatory activities; and biobased raw materials for industry from their CO2 emissions.

The company was incorporated in 2009 and is headquartered in Libourne, France.

Stock analysis

Fermentalg SA (ALGAE) currently trades at €0.3900, while our estimate is €0.3522, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.2642 (bear) to €0.4403 (bull), the price of €0.3900 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Fermentalg SA reported revenue of €13.4M in FY2025 versus €5.6M in FY2021, a compound +24.1%/yr. Reported net income was −€9.4M in FY2025.

Key figures

Market cap €46.7M Micro · P/S ratio 3.54 · EPS (TTM) €−0.0900 · Net margin −70.6% · Return on equity −29.9% · Return on assets (EBIT) −19.9% (5-year average) · Operating margin −68.7% · Revenue (TTM) €13.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, ALGAE screens richer than that median.

Fair Value

Bear €0.2642 Fair Value €0.3522 Bull €0.4403
Price €0.3900 · Downside -9.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 64
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 44
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+16.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.4%
Start year 2020 (pandemic). Over 10 years: +23.2% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−469.6% (2020) → −70.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALGAE screens overvalued: fair value 10% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Fermentalg SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −9.7% · Top 25%
Profitability
Return on assets −25.9% · Below median
Net margin (12 months) −70.6% · Bottom 25%
Operating margin (12 months) −68.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −2.5% · Below median
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.85× · Cheaper than median
P/S (12 months) 3.54× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ALGAE
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ALGAE
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ALGAE
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ALGAE
argenx SE ARGX $971.55 $908.40 −7% vs ALGAE
CSL Limited CSL A$201.68 A$181.40 −10% vs ALGAE
Moderna, Inc MRNA $250.83 $158.70 −37% vs ALGAE
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ALGAE
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ALGAE
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ALGAE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fermentalg SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Fermentalg SA Fair Value". https://www.fairvalue-calculator.com/stock/ALGAE

Frequently asked questions

Is Fermentalg SA (ALGAE) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €0.3522 versus a price of €0.3900, about 10% lower (overvalued).
What is the fair value of ALGAE?
Our estimate for Fermentalg SA is €0.3522 (as of Nov 10, 2026), built from audited fundamentals. The current price: €0.3900.
What is the quality score of ALGAE?
Fermentalg SA has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fermentalg SA (ALGAE)?
Our calculated price target is the estimate of €0.3522 (as of Nov 10, 2026). Cautious scenario €0.2642, optimistic scenario €0.4403. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Fermentalg SA stock forecast for 2026?
Our estimate puts fair value at €0.3522, about 10% lower versus a price of €0.3900 (overvalued). Cautious scenario €0.2642, optimistic scenario €0.4403. The calculation is refreshed regularly with new filings.
What is the revenue of Fermentalg SA (ALGAE)?
Fermentalg SA reported trailing-twelve-month revenue of about €13.2M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Fermentalg SA (ALGAE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fermentalg SA it is €0.3522 per share (as of Nov 10, 2026), against a price of €0.3900.
Is Fermentalg SA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ALGAE trades above its calculated fair value: price €0.3900, fair value €0.3522, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALGAE?
No. The price is what the market pays today (€0.3900); the fair value is what the company's own numbers justify (€0.3522). For Fermentalg SA the two are €0.0378 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fermentalg SA worth?
The market values Fermentalg SA at about €46.7M (market capitalisation, as of Nov 10, 2026). Per share that is €0.3900; our models calculate a fair value of €0.3522 per share.
What do the bullish and bearish scenarios say about ALGAE?
Our models span a range for Fermentalg SA: cautious scenario €0.2642, base €0.3522, optimistic €0.4403 per share (as of Nov 10, 2026, price €0.3900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Fermentalg SA (ALGAE)?
Balance-sheet figures for Fermentalg SA (as of Nov 10, 2026): return on equity −29.9%, debt of 0.15 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is ALGAE from its 52-week high?
Fermentalg SA trades at €0.3900, about 38% below its 52-week high of €0.6300 and 6% above the low of €0.3680 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €0.3522 is for.
Which stocks are comparable to Fermentalg SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fermentalg SA stock attractive at the current price?
The data as of Nov 10, 2026: price €0.3900, calculated fair value €0.3522 (−10%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Fermentalg SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fermentalg SA (ALGAE)?
The closing price on Nov 10, 2026 was €0.3900. Our estimate is €0.3522, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fermentalg SA right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Fermentalg SA

How large is the market capitalisation of Fermentalg SA (ALGAE)?
The market capitalisation of Fermentalg SA is €46.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fermentalg SA (ALGAE)?
The price-to-sales ratio of Fermentalg SA is 3.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fermentalg SA (ALGAE)?
Earnings per share at Fermentalg SA are €−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fermentalg SA (ALGAE)?
The net margin of Fermentalg SA is −70.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fermentalg SA (ALGAE)?
The return on equity (ROE) of Fermentalg SA is −29.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fermentalg SA (ALGAE)?
On an EBIT basis the return on assets of Fermentalg SA is −19.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fermentalg SA (ALGAE)?
The operating margin of Fermentalg SA is −68.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fermentalg SA (ALGAE)?
Revenue at Fermentalg SA is growing −2.5% versus a year earlier (3y avg +20.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Fermentalg SA (ALGAE) generate?
The free cash flow of Fermentalg SA is −€8.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Fermentalg SA (ALGAE) hold?
Fermentalg SA holds more cash than debt, €1.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Fermentalg SA in the live analysis

One click puts Fermentalg SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.